XML 41 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 43,952 $ 30,268 $ 75,876 $ 59,710
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 14,323 0 14,323 0
Development and Other Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 29,629 30,268 61,553 59,710
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 14,323 0 14,323 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Astellas Agreement [Member] | Development and Other Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 1,142 317 1,591 613
Astellas Agreement [Member] | Development and Other Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 5,003 4,781 9,726 9,171
AstraZeneca Agreements [Member] | China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
AstraZeneca Agreements [Member] | Development and Other Revenue [Member] | U.S./RoW [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 23,479 $ 25,167 $ 50,202 $ 49,923